Boehringer Ingelheim Acquires Viral-Based Cancer Immunotherapy Developer ViraTherapeutics

Boehringer Ingelheim has exercised its option to buy ViraTherapeutics for €210 million ($245 million), the buyer and the acquired company’s co-lead investor EMBL Ventures said, in a deal that gives Boehringer full control over a preclinical viral-based cancer immunotherapy the companies have been co-developing for two years.EMBL Ventures is an early-stage European life science venture capital firm that first invested in the company in 2015 as part of its €3.6 million ($4.2 millio